Lanean...
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
While a fraction of cancer patients treated with anti–PD-1 show durable therapeutic responses, most remain unresponsive, highlighting the need to better understand and improve these therapies. Using an in vivo screening approach with a customized shRNA pooled library, we identified DDR2 as a leading...
Gorde:
| Argitaratua izan da: | Sci Adv |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Association for the Advancement of Science
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6382401/ https://ncbi.nlm.nih.gov/pubmed/30801016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aav2437 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|